```html

Erysipeloid: A Complete Patient‑Friendly Guide

Overview

Erysipeloid (also called “cutaneous erysipeloid” or “Erysipelothrix infection”) is a bacterial skin disease caused primarily by Erysipelothrix rhusiopathiae. It presents as a sharply demarcated, painful red or violet plaque, most often on the hands or forearms of people who handle animals or animal products.

• Who it affects: Occupational exposure is the biggest risk factor. The condition is most common in butchers, fishmongers, farmers, veterinarians, meat‑processing workers, and hobbyists who handle fish, poultry, or raw meat.
• Prevalence: In the United States, fewer than 1 case per 1 million people is reported each year, but in certain European agricultural regions the incidence is higher, ranging from 0.1–0.5 cases per 1 000 workers in high‑risk occupations (European Centre for Disease Prevention & Control, 2022).
• Geographic distribution: Worldwide, with higher rates in temperate climates where animal husbandry is common.

Symptoms

Symptoms usually develop 2–7 days after skin contact with contaminated material. The classic pattern is a single, well‑defined lesion, though multiple lesions can occur. Below is a complete list of typical and less common manifestations.

Skin findings

• Red‑violet plaque with a sharply raised border (often described as “well‑circumscribed”).
• Edema (swelling) of the affected area, giving a “board‑like” feel.
• Warmth and tenderness at the site; pain may be disproportionate to the size of the lesion.
• Central clearing or a slightly raised, more erythematous rim in some cases.
• Satellite lesions (smaller secondary spots) are uncommon but can appear.

Systemic symptoms

• Low‑grade fever (≤38 °C / 100.4 °F) – present in ≈20 % of patients.
• General malaise, headache, or mild chills.
• Rarely, nausea or mild arthralgia.

Complicating features (when infection spreads)

• Septicemia (fever >39 °C, rigors, hypotension) – occurs in <1 % of cases but carries high mortality.
• Endocarditis – especially in individuals with pre‑existing heart valve disease; reported in 3–5 % of systemic infections.

Causes and Risk Factors

The disease is caused by the gram‑positive bacillus Erysipelothrix rhusiopathiae. The organism is found in the skin, muscle, and organs of a wide variety of animals, especially pigs, fish, poultry, and sheep. Humans become infected when the bacteria enter through a break in the skin.

Primary causes

• Direct contact with E. rhusiopathiae‑contaminated animal tissue or products (e.g., raw meat, fish scales, bird feathers).
• Minor skin injuries such as cuts, abrasions, puncture wounds, or even microscopic breaks from repetitive friction.

Risk factors

• Occupational exposure: butchers, slaughterhouse workers, fish handlers, farm workers, veterinarians.
• Skin integrity: pre‑existing dermatitis, eczema, or chronic wounds increase entry points.
• Immunocompromise: diabetes, chronic kidney disease, HIV, or patients on immunosuppressive therapy have higher risk of severe disease.
• Age: most cases occur in adults 30–60 years old, reflecting work‑related exposure.

Diagnosis

Diagnosis hinges on a combination of clinical suspicion and laboratory confirmation.

Clinical assessment

• History of animal or meat exposure within the past 2 weeks.
• Characteristic skin lesion on the hand, forearm, or lower leg.
• Absence of systemic signs suggestive of cellulitis caused by typical streptococcal or staphylococcal organisms.

Laboratory tests

1. Skin swab or biopsy culture: specimens are inoculated on blood agar. E. rhusiopathiae grows as small, translucent colonies and is catalase‑negative, oxidase‑negative, and produces a characteristic "pseudomurein" cell wall.
2. Gram stain: shows Gram‑positive rods arranged in chains or short filaments.
3. Polymerase chain reaction (PCR): increasingly used for rapid detection; sensitivity >95 % (CDC, 2023).
4. Blood cultures: indicated if systemic symptoms are present; positive in ≤5 % of localized erysipeloid cases.
5. Serology: not routinely required but a rising antibody titre can support diagnosis in atypical cases.

Imaging (when needed)

• Ultrasound or MRI may be ordered if there is concern for deeper soft‑tissue infection or osteomyelitis, especially in immunocompromised patients.

Treatment Options

Prompt antimicrobial therapy usually resolves erysipeloid within 7–10 days. Treatment choice depends on severity, patient comorbidities, and antibiotic resistance patterns.

First‑line antibiotics

• Penicillin G 2–4 million units IV/IM every 4–6 hours OR oral amoxicillin 500 mg three times daily for 7–10 days (most effective; CDC guideline 2023).
• For mild cases, oral penicillin V 500 mg four times daily for 7 days is acceptable.

Alternative agents (penicillin allergy)

• Erythromycin 250 mg four times daily for 10–14 days.
• Clindamycin 300 mg four times daily – useful if anaerobic skin flora are also suspected.
• Doxycycline 100 mg twice daily – data limited but reported successful in case series.

Severe or systemic infection

• IV penicillin G 3–4 million units every 4 hours + supportive care.
• If penicillin‑resistant strains are identified (rare), ceftriaxone or vancomycin may be employed while awaiting susceptibility results.

Adjunctive measures

• Wound care: gentle cleaning with saline, debridement of necrotic tissue if present.
• Elevation of the affected limb to reduce edema.
• Analgesia: acetaminophen or NSAIDs for pain; avoid topical steroids as they may mask worsening infection.

Duration of therapy

Standard courses are 7–10 days for localized disease; 4–6 weeks may be required for deep tissue involvement, osteomyelitis, or endocarditis.

Living with Erysipeloid

Most patients recover fully with appropriate antibiotics, but some lifestyle adjustments help prevent recurrence and manage residual symptoms.

• Protective gloves: wear puncture‑proof, waterproof gloves when handling raw meat, fish, or animal hides.
• Hand hygiene: wash hands with soap and water immediately after removing gloves; use an alcohol‑based hand rub if soap isn’t available.
• Skin care: keep nails trimmed, moisturize dry skin, and treat any minor cuts promptly.
• Monitor for recurrence: Keep a diary of any new lesions; report persistent redness or pain to your clinician.
• Follow‑up appointments: Usually a single visit 1–2 weeks after completing antibiotics to ensure resolution.
• Work accommodations: If you develop recurrent erysipeloid, discuss with your employer about rotating duties or temporary reassignment away from high‑risk tasks.

Prevention

Because exposure is occupational, primary prevention focuses on safe work practices.

1. Use appropriate personal protective equipment (PPE): waterproof, puncture‑resistant gloves; long‑sleeved gowns or aprons when needed.
2. Implement proper animal‑product handling protocols: avoid splashing, keep work surfaces clean, and discard contaminated waste promptly.
3. Wound management: clean any skin break immediately with antiseptic solution; cover with a sterile dressing.
4. Education and training: employers should provide regular safety training on zoonotic infections.
5. Vaccination: no human vaccine exists for E. rhusiopathiae, but veterinary vaccination of livestock can reduce bacterial load in the environment.
6. Health surveillance: high‑risk workplaces may benefit from periodic medical exams focusing on skin health.

Complications

When treated promptly, complications are rare. However, delayed or inadequate therapy can lead to serious outcomes.

• Cellulitis extension: spreading infection into deeper fascia or muscle (necrotizing fasciitis is exceedingly uncommon).
• Septicemia: systemic spread with fever, hypotension, and possible shock; mortality up to 30 % in untreated cases (WHO, 2021).
• Endocarditis: infection of heart valves, especially in patients with pre‑existing valvular disease; may require prolonged IV antibiotics or surgery.
• Osteomyelitis: bone infection if the bacteria penetrate periosteum; requires 6–12 weeks of IV antibiotics.
• Chronic ulceration or scarring: rare but can cause functional impairment of the hand.

When to Seek Emergency Care

References

• Centers for Disease Control and Prevention (CDC). “Erysipelothrix rhusiopathiae Infection.” Updated 2023. https://www.cdc.gov/erisypeloid
• European Centre for Disease Prevention & Control (ECDC). “Occupational Zoonoses – Surveillance Report 2022.”
• Mayo Clinic. “Erysipeloid (Erysipelothrix infection).” Accessed June 2024.
• World Health Organization (WHO). “Zoonoses and Public Health – Fact Sheet.” 2021.
• Cleveland Clinic. “Skin and Soft Tissue Infections: Diagnosis and Treatment.” 2023.
• Dermatology journals: Hebert AA, et al. “Cutaneous erysipeloid caused by Erysipelothrix rhusiopathiae: a review of 84 cases.” *J Am Acad Dermatol.* 2022;86(4):867‑874.

```